Hodgkin lymphoma: 2023 update on diagnosis, risk‐stratification, and management
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hodgkin lymphoma: 2023 update on diagnosis, risk‐stratification, and management
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 97, Issue 11, Pages 1478-1488
Publisher
Wiley
Online
2022-09-07
DOI
10.1002/ajh.26717
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Positron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study
- (2022) René-Olivier Casasnovas et al. JOURNAL OF CLINICAL ONCOLOGY
- Response-adapted anti-PD1 based salvage therapy for Hodgkin lymphoma with nivolumab +/- ICE (NICE)
- (2022) Matthew G. Mei et al. BLOOD
- The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee
- (2022) Elias Campo et al. BLOOD
- The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years
- (2022) Ali Bazarbachi et al. LEUKEMIA
- A Real-World Study of Combined Modality Therapy for Early-Stage Hodgkin Lymphoma: Too Little Treatment Impacts Outcome
- (2022) Karan L. Chohan et al. Blood Advances
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
- (2022) Rita Alaggio et al. LEUKEMIA
- Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
- (2022) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
- (2021) John Kuruvilla et al. LANCET ONCOLOGY
- Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)
- (2021) Sarah Gillessen et al. Lancet Haematology
- Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
- (2021) Alison J. Moskowitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
- (2021) Carla Damaschin et al. LEUKEMIA
- Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
- (2021) Mehdi Hamadani et al. Lancet Haematology
- Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial
- (2021) Alex F. Herrera et al. Blood Advances
- Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow‐up of the multicenter, single‐arm, Phase 2 study
- (2021) Jianqiu Wu et al. INTERNATIONAL JOURNAL OF CANCER
- Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years
- (2020) Christopher A. Yasenchak et al. BLOOD
- Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG
- (2020) Michael S Binkley et al. BLOOD
- Impact of type of reduced‐intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma
- (2020) Sairah Ahmed et al. BRITISH JOURNAL OF HAEMATOLOGY
- Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
- (2020) Marie José Kersten et al. HAEMATOLOGICA
- Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma
- (2020) Paul J. Bröckelmann et al. JAMA Oncology
- Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
- (2020) Carlos A. Ramos et al. JOURNAL OF CLINICAL ONCOLOGY
- ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma
- (2020) Steven I. Park et al. Blood Advances
- Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma
- (2020) Pamela Blair Allen et al. BLOOD
- Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
- (2020) Catherine S Diefenbach et al. Lancet Haematology
- Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients
- (2020) Luca Castagna et al. BMC CANCER
- Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
- (2019) Yuankai Shi et al. Lancet Haematology
- PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
- (2019) Philippe Armand et al. BLOOD
- Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study
- (2019) Sally F. Barrington et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
- (2019) Radhakrishnan Ramchandren et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab Vedotin, Doxorubicin, Vinblastine and Dacarbazine for Non-bulky Limited Stage Classical Hodgkin Lymphoma
- (2019) Jeremy S. Abramson et al. BLOOD
- Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
- (2019) Robert Chen et al. BLOOD
- Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
- (2019) Yuqin Song et al. LEUKEMIA
- Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?
- (2019) Mattia Novo et al. LEUKEMIA & LYMPHOMA
- Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
- (2018) Ann S. LaCasce et al. BLOOD
- Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
- (2018) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma
- (2018) Andrew M. Evens et al. JOURNAL OF CLINICAL ONCOLOGY
- Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
- (2017) Marc P.E. André et al. JOURNAL OF CLINICAL ONCOLOGY
- PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study
- (2016) S. F. Barrington et al. BLOOD
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
- (2016) Chun-Meng Wang et al. CLINICAL CANCER RESEARCH
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
- (2016) Peter Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
- (2015) Alison J Moskowitz et al. LANCET ONCOLOGY
- Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
- (2015) John Radford et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis
- (2013) Nicole Skoetz et al. LANCET ONCOLOGY
- Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
- (2013) Anas Younes et al. LANCET ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)
- (2012) Leo I. Gordon et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
- (2012) Andreas Engert et al. LANCET
- Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi
- (2011) Teodoro Chisesi et al. JOURNAL OF CLINICAL ONCOLOGY
- ABVD versus BEACOPP for Hodgkin's Lymphoma
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Hodgkin's Lymphoma — The Great Teacher
- (2011) Joseph M. Connors NEW ENGLAND JOURNAL OF MEDICINE
- ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
- (2011) Simonetta Viviani et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma
- (2011) Ralph M. Meyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma
- (2010) Sally F. Barrington et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial
- (2010) Hans Theodor Eich et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
- (2010) Andreas Engert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study
- (2009) Andreas Engert et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244
- (2009) Peter J. Hoskin et al. JOURNAL OF CLINICAL ONCOLOGY
- ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
- (2009) Massimo Federico et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started